News + Resources

Innovations Advanced by M&A: A Cure for Inherited Blindness

Innovations Advanced by M&A: A Cure for Inherited Blindness

Across the United States’ world-class life sciences ecosystem, mergers and acquisitions (M&A) have become a vital bridge for companies to secure the resources, investment and expertise necessary to bring new treatments and cures to patients. Case in point: the 2019 merger between Roche and Spark Therapeutics that was instrumental in helping to expand the global reach of Luxturna, a first-in-class gene therapy approved as a one-time treatment for biallelic RPE65 mutation-associated retinal dystrophy – a rare, inherited form of vision loss.

read more